Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leukocyte-platelet-rich fibrin (L-PRF) is an autologous, second-generation platelet concentrate biologic primarily used in oral, dental, and maxillofacial surgery to enhance wound healing and tissue regeneration. It is prepared by centrifuging a patient's own blood without anticoagulants to create a dense fibrin matrix enriched with leukocytes, platelets, and a high concentration of growth factors. This matrix acts as a biological scaffold that gradually releases bioactive molecules, such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), to promote angiogenesis and tissue repair. L-PRF is currently being evaluated by institutions like the Universidad Austral de Chile for applications such as preserving tooth socket tissue structure following third molar extractions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leukocyte-platelet-rich fibrin.